Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe, EditForce Join Forces for Discovery of Gene Therapy in CNS
June 28, 2022
- Kyowa Kirin Gets EU Backing for Crysvita’s Label Expansion into TIO
June 28, 2022
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- Daiichi Sankyo CEO Snags 341 Million Yen in FY2021: Securities Filing
June 28, 2022
- Bimzelx as Driver, UCB Set to Derive Half of Global Sales from Immunology Biz
June 28, 2022
- Ex-Wakamoto Chairman Misused 1.7 Million Yen from Company’s Coffers
June 27, 2022
- Takeda to Absorb Nihon Pharmaceutical in October
June 27, 2022
- Ono Chief Pledges to Boost Compliance after Bribery Case
June 24, 2022
- 25 Japan Drug Makers Log Combined 10.7% Growth in FY2021, 12 See Two-Digit Jumps: Tally
June 24, 2022
- JCR Executive Pay Tops 100 Million Yen for First Time in FY2021
June 24, 2022
- Pfizer Curbs Stelues Shipment in Japan on Spike in Demand
June 23, 2022
- EMA Starts Enhertu Review for HER2 Low Breast Cancer
June 23, 2022
- Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus
June 22, 2022
- Alinamin Invites New President from Non-Pharma Sector
June 22, 2022
- Tokyo Wholesaler Slapped with 10-Day Biz Suspension over Fake Triazolam API
June 22, 2022
- Taiho Lifts Shipment Control on Abraxane
June 21, 2022
- ASKA Licenses Korean Rights for Birth Control Pill Drospirenone
June 21, 2022
- Astellas Workforce Down by More than 700: Securities Report
June 21, 2022
- PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy
June 20, 2022
- Kyorin Snags Rights to Genetically Modified Adipocytes for Fabry Disease
June 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…